In short
Overview
Weight comes back after stopping a GLP-1. That is not a failure of willpower and it is not a surprise to anyone who has read the trials. It is what the drug class does.
Direct Answer
Across 37 studies and over 9300 participants, average regain after stopping was 0.4 kg per month, with a projected return to starting weight within about two years.
In one trial, people who stayed on semaglutide kept losing weight while those switched to placebo regained significantly by 48 weeks.
This is why obesity is treated as a chronic condition and why long term treatment is the standard position of the World Health Organization and the American Diabetes Association.
Who This Applies To
- Anyone stopping a GLP-1 for cost reasons
- Anyone stopping because they reached their goal
- Anyone whose supply has been interrupted
- Anyone considering starting and wanting to know what they are committing to
Option Comparison / Decision Criteria
The numbers on stopping
| Average regain | 0.4 kg per month across 37 studies |
| Projected return to baseline | Within about two years |
| Metabolic benefits | Reverse alongside the weight, shown for tirzepatide |
What about a lower maintenance dose?
This was tested directly, and the result is useful. In a trial of 378 people who had lost at least 5 per cent on tirzepatide and tolerated at least 10 mg, three groups were compared over 52 weeks of maintenance.
| Maximum tolerated dose | 21.9 per cent below starting weight. 11 per cent regained half their loss |
| Reduced 5 mg dose | 16.6 per cent below starting weight. 25 per cent regained half their loss |
| Placebo | 9.9 per cent below starting weight. 67 per cent regained half their loss |
So a reduced dose holds considerably more than stopping, and considerably less than staying on the full dose.
What that means in practice
Once treatment targets are reached, the same dose is usually continued for maintenance rather than reduced, because reducing it tends to lead to regain and to worsening of the metabolic measures.
The exception is someone losing beyond their goal weight, where a reduction makes sense.
Why an In-Person Physician Review Matters
Why this needs planning rather than reacting Because regain is predictable, it can be planned for.
What does not work is stopping abruptly and hoping. The behavioural side matters here. Behavioural intervention and lifestyle change are the foundation of treatment and are continued for anyone on medication, not replaced by it. Where medication stops, that foundation is what remains. If you have to stop Have a plan for the eating and activity side before the last dose, not after Expect regain and monitor weight so that it is caught early rather than at the next annual check Know that restarting is possible and that it is not an admission of failure If cost is the reason Cost and access are frequently the primary consideration in choosing an agent, and that is a legitimate clinical factor rather than an awkward one. There are less expensive options, including liraglutide and non GLP-1 agents such as phentermine and topiramate, which are less effective but considerably cheaper. A cheaper drug you can continue usually beats a better drug you have to stop. The framing that helps Nobody expects blood pressure to stay down after stopping a blood pressure tablet. Obesity is described in the same terms: a chronic condition where most people require long term therapy.
Frequently Asked Questions
About 0.4 kg per month on average, across 37 studies and over 9300 participants, with a projected return to starting weight within roughly two years.
Yes, and it holds a lot of the benefit. In a 52 week trial, people on a reduced 5 mg maintenance dose of tirzepatide stayed 16.6 per cent below baseline against 21.9 per cent on the full dose and 9.9 per cent on placebo.
It can be, particularly if side effects or cost make continuing unrealistic. But it should be a planned decision with the eating and activity side in place first, and with weight monitored so regain is caught early.
It reverses alongside the weight. That has been shown for tirzepatide, and it is the main reason long term treatment is recommended rather than a course of treatment.
Evidence
Where this information comes from
Every figure on this page is taken from the sources below. All of them are free to read, so you can check them yourself.
- Wegovy: European public assessment report
- Mounjaro: European public assessment report
- Semaglutide for managing overweight and obesity
- Obesity and overweight
This page is general medical information and does not replace a personal consultation. Trial results are averages across large groups, not a prediction for any one person.